Global Thalassemia Market Size study & Forecast, by Therapeutic Class (Iron Chelating Drugs), by Pipeline (Gene Therapy) and Regional Analysis, 2022-2029

Global Thalassemia Market Size study & Forecast, by Therapeutic Class (Iron Chelating Drugs), by Pipeline (Gene Therapy) and Regional Analysis, 2022-2029

Global Thalassemia Market is valued approximately USD 2.58 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2022-2029. According to Centers for Disease Control and Prevention - Thalassemia can be defined as an inherited blood disorder caused when the body doesn't make enough hemoglobin. Hemoglobin is an important part of red blood cells. Thalassemia is a treatable disorder that can be well-managed with blood transfusions and chelation therapy. There are different types of signs and symptoms associated with thalassemia including Fatigue. Weakness, Pale or yellowish skin, Facial bone deformities, Slow growth, Abdominal swelling., and Dark urine among others. The increasing prevalence of blood disorders and growing adoption of blood transfusion and iron chelation therapies are key factors driving the market growth.

The increasing prevalence of blood disorders is contributing towards the growth of the Global Thalassemia Market. For instance – according to Indian Academy of Pediatrics (IPA) estimates – as of 2021, approximately 10% of the total world incidence of thalassemia-affected children and one in eight of thalassemia carriers live in India. Additionally, as per World Health organization (WHO) estimates - Beta-thalassemia affects 2.9% of the world's population. Also, growing healthcare industry in developing regions and increasing number of clinical trials for blood disorders would create lucrative growth prospectus for the market over the forecast period. However, the high cost associated with Thalassemia treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Thalassemia Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing incidences of thalassemia and rise in spending in health infrastructure in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing incidences of blood related disorders as well as rapid expansion of contract manufacturing organizations in the region.

Major market player included in this report are:
Bluebird Bio Inc.
Acceleron Pharma, Inc.
Celgene Corporation
GlaxoSmithKline plc
Incyte Corporation
Gamida Cell
Kiadis Pharma
La Jolla Pharmaceutical Company
IONIS Pharmaceuticals
Novartis AG

Recent Developments in the Market:
 In August 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy intended for the treatment of adult and pediatric patients affected by beta-thalassemia.

Global Thalassemia Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapeutic Class, Pipeline, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class
Iron Chelating Drugs

By Pipeline
Gene Therapy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Bluebird Bio Inc.
Acceleron Pharma, Inc.
Celgene Corporation
GlaxoSmithKline plc
Incyte Corporation
Gamida Cell
Kiadis Pharma
La Jolla Pharmaceutical Company
IONIS Pharmaceuticals
Novartis AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.